The effect of a heparin-based coacervate of fibroblast growth factor-2 on scarring in the infarcted myocardium

Biomaterials

Volumn 34, Issue 6, 2013, Pages 1747-1756

  Chu, Hunghao ^a   Chen, Chien Wen ^a,b   Huard, Johnny ^b,c   Wang, Yadong ^a,b  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Coacervate; Controlled release; Fibroblast growth factor; Heparin; Myocardial infarction

Indexed keywords

COACERVATE; CONTROLLED RELEASE; FIBROBLAST GROWTH FACTOR; HEPARIN; MYOCARDIAL INFARCTION;

BIOACTIVITY; CONTROL SYSTEM SYNTHESIS; DISEASE CONTROL; ENDOTHELIAL CELLS; PROTEINS; TISSUE;

POLYSACCHARIDES;

FIBROBLAST GROWTH FACTOR 2; HEPARIN; POLYCATION; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; CELL DEATH; COACERVATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; FUNCTIONAL ASSESSMENT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; FIBROBLAST GROWTH FACTOR 2; HEPARIN; MALE; MICE; MICE, INBRED BALB C; MYOCARDIAL INFARCTION;

ANIMALIA; RODENTIA;

EID: 84870813906     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.019     Document Type: Article

References (54)

1. Members W.G., Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., et al. Heart disease and stroke statistics-2012 update. Circulation 2012, 125:e2-e220.
2. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994, 93:662-670.
3. Freedman S.B., Isner J.M. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001, 33:379-393.
4. Sieveking D.P., Ng M.K. Cell therapies for therapeutic angiogenesis: back to the bench. Vas Med 2009, 14:153-166.
5. Annex B.H., Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovas Res 2005, 65:649-655.
6. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
7. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998, 141:1659-1673.
8. Zhang J., Cao R., Zhang Y., Jia T., Cao Y., Wahlberg E. Differential roles of PDGFR-α and PDGFR-β in angiogenesis and vessel stability. FASEB J 2009, 23:153-163.
9. Murakami M., Nguyen L.T., Hatanaka K., Schachterle W., Chen P.-Y., Zhuang Z.W., et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest 2011, 121:2668-2678.
10. Murakami M., Nguyen L.T., Zhang Z.W., Moodie K.L., Carmeliet P., Stan R.V., et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008, 118:3355-3366.
11. Jiang Z.-S., Srisakuldee W., Soulet F., Bouche G., Kardami E. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovas Res 2004, 62:154-166.
12. Rosenblatt-Velin N., Lepore M.G., Cartoni C., Beermann F., Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005, 115:1724-1733.
13. Aviles R.J., Annex B.H., Lederman R.J. Testing clinical therapeutic angiogenesis using fibroblast growth factor (FGF-2). Br J Pharmacol 2003, 140:637-646.
14. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999, 100:1865-1871.
15. Ruel M., Laham R.J., Parker J.A., Post M.J., Ware J.A., Simons M., et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002, 124:28-34.
16. Laham R.J., Chronos N.A., Pike M., Leimbach M.E., Udelson J.E., Pearlman J.D., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000, 36:2132-2139.
17. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Circulation 2002, 105:788-793.
18. van Royen N., Piek J.J., Schaper W., Fulton W.F. A critical review of clinical arteriogenesis research. J Am Coll Cardiol 2010, 55:17-25.
19. Zern B.J., Chu H., Wang Y. Control growth factor release using a self-assembled [polycation:heparin] complex. PLoS One 2010, 5:e11017.
20. Chu H., Johnson N.R., Mason N.S., Wang Y. A [polycation:heparin] complex releases growth factors with enhanced bioactivity. J Control Release 2011, 150:157-163.
21. Chu H., Gao J., Chen C.-W., Huard J., Wang Y. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. Proc Natl Acad Sci 2011, 108:13444-13449.
22. Chu H., Gao J., Wang Y. Design, synthesis, and biocompatibility of an arginine-based polyester. Biotech Prog 2012, 28:257-264.
23. Oshima H., Payne T.R., Urish K.L., Sakai T., Ling Y., Gharaibeh B., et al. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol Ther 2005, 12:1130-1141.
24. Okada M., Payne T.R., Zheng B., Oshima H., Momoi N., Tobita K., et al. Myogenic endothelial cells purified from human skeletal muscle improve cardiac function after transplantation into infarcted myocardium. J Am Coll Cardiol 2008, 52:1869-1880.
25. Oshima G., Uchiyama H., Nagasawa K. A new method for determining the dissociation constant between macromolecules by gel permeation. Anal Biochem 1981, 111:366-371.
26. Hattori T., Kimura K., Seyrek E., Dubin P.L. Binding of bovine serum albumin to heparin determined by turbidimetric titration and frontal analysis continuous capillary electrophoresis. Anal Biochem 2001, 295:158-167.
27. Lee M.K., Lander A.D. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc Natl Acad Sci 1991, 88:2768-2772.
28. Krishnamurthy P., Rajasingh J., Lambers E., Qin G., Losordo D.W., Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 2009, 104:e9-e18.
29. Sutton M.G.S.J., Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation 2000, 101:2981-2988.
30. Leader B., Baca Q.J., Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7:21-39.
31. Edelman E.R., Nugent M.A., Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci 1993, 90:1513-1517.
32. Lazarous D.F., Shou M., Stiber J.A., Dadhania D.M., Thirumurti V., Hodge E., et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovas Res 1997, 36:78-85.
33. Singelyn J.M., Sundaramurthy P., Johnson T.D., Schup-Magoffin P.J., Hu D.P., Faulk D.M., et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol 2012, 59:751-763.
34. Mehta J.L., Li D.Y. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovas Res 1999, 43:291-299.
35. Peppas N.A., Hilt J.Z., Khademhosseini A., Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater 2006, 18:1345-1360.
36. Smith J.D., Chen A., Ernst L.A., Waggoner A.S., Campbell P.G. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels. Bioconjug Chem 2007, 18:695-701.
37. Xu X., Jha A.K., Harrington D.A., Farach-Carson M.C., Jia X. Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks. Soft Matter 2012, 8:3280-3294.
38. Ruvinov E., Leor J., Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 2010, 31:4573-4582.
39. Jeon O., Powell C., Solorio L.D., Krebs M.D., Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. J Control Release 2011, 154:258-266.
40. Zustiak S.P., Leach J.B. Characterization of protein release from hydrolytically degradable poly(ethylene glycol) hydrogels. Biotechnol Bioeng 2011, 108:197-206.
41. Garbern J.C., Minami E., Stayton P.S., Murry C.E. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011, 32:2407-2416.
42. Kokai L.E., Tan H., Jhunjhunwala S., Little S.R., Frank J.W., Marra K.G. Protein bioactivity and polymer orientation is affected by stabilizer incorporation for double-walled microspheres. J Control Release 2010, 141:168-176.
43. Stanwick J.C., Baumann M.D., Shoichet M.S. Enhanced neurotrophin-3 bioactivity and release from a nanoparticle-loaded composite hydrogel. J Control Release 2012, 160:666-675.
44. Ye M., Kim S., Park K. Issues in long-term protein delivery using biodegradable microparticles. J Control Release 2010, 146:241-260.
45. Powell A.K., Yates E.A., Fernig D.G., Turnbull J.E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004, 14:17R-30R.
46. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: heparin. Circulation 2001, 103:2994-3018.
47. Ashikari-Hada S., Habuchi H., Kariya Y., Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. J Biol Chem 2005, 280:31508-31515.
48. Goodger S.J., Robinson C.J., Murphy K.J., Gasiunas N., Harmer N.J., Blundell T.L., et al. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 2008, 283:13001-13008.
49. Wijelath E., Namekata M., Murray J., Furuyashiki M., Zhang S., Coan D., et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem 2010, 111:461-468.
50. Sakata H., Stahl S.J., Taylor W.G., Rosenberg J.M., Sakaguchi K., Wingfield P.T., et al. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. J Biol Chem 1997, 272:9457-9463.
51. Nie T., Baldwin A., Yamaguchi N., Kiick K.L. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J Control Release 2007, 122:287-296.
52. Seal B.L., Panitch A. Physical polymer matrices based on affinity interactions between peptides and polysaccharides. Biomacromolecules 2003, 4:1572-1582.
53. Rajangam K., Behanna H.A., Hui M.J., Han X., Hulvat J.F., Lomasney J.W., et al. Heparin binding nanostructures to promote growth of blood vessels. Nano Lett 2006, 6:2086-2090.
54. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struc Biol 2001, 11:629-634.